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USEFULNESS OF ELECTRONIC HORMONAL FERTILITY 
MONITORING FOR AVOIDING PREGNANCY 
RICHARD J. FEHRING 
Couples wishing to achieve or avoid pregnancy can now use 
an electronic hormonal fertility monitor to aid home fertility 
monitoring. The Clearplan Easy Fertility Monitor (CPFM) is a 
handheld monitor designed to help couples achieve pregnancy. 
It provides information on three levels of fertility (low, high, and 
peak) based on urinary threshold levels of estrogen and lutein-
izing hormone (LH). The monitor can be used as an aid to avoid 
pregnancy when used with another marker of fertility. We con-
ducted an efficacy study co determine che effectiveness of using the 
monitor along with cervical mucus monitoring with 215 couples 
seeking co avoid pregnancy and found a correct-use unintended 
pregnancy rate of 2.0% per annum and a total pregnancy race of 
13.0% per annum. These same couples rated the monitor easy to 
use and helpful based on a ten-item survey. Overall, the monitor 
is not perfect, but can be useful for couples who wish to have an 
objective device for fertility monitoring. 
I
n 1990, Carl Djerassi, one of the developers of the first hor-
monal contraceptive pill, published an article in Science maga-
zine stating that in the future there will be what he called Jet 
Age natural family planning (NFP) (Djerassi 1990). In the article, 
he described a method of NFP whereby women would be able to 
measure reproductive hormones in their urine to estimate the fer-
tile phase of the menstrual cycle. Six years later, Unipath scientists 
introduced a handheld fertility monitor, called Persona, which was 
designed to read test strips impregnated with antibodies from two 
reproductive hormones (estrone 3 glucuronide and luteinizing hor-
mone, i.e., E3G and LH) and provide the user with an indication 
of fertility (with a red light) and infertility (with a green light) (May 
1997). A prototype of Persona was tested as a contraceptive device in 
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Europe and, with an adjustment of its internal algorithm, is now sold 
in Europe but not in the United States. 
A similar device called ClearPlan (or ClearBlue) Easy Fertility 
Monitor (CPFM) is sold in the United States as a device to help cou-
ples achieve pregnancy (May 2001; Spieler and Collins 2001). Like 
Persona, the CPFM is a handheld device that measures threshold 
levels of urinary E3G and LH. However, unlike Persona, the CPFM 
provides three levels of fertility-low, high (based on reaching a 
threshold of E3G), and peak fertility (based on reaching a threshold 
of urinary LH) (May 2001; Unipath Diagnostics 2001). Since the 
device is designed to enhance the ability to achieve pregnancy, it 
does not always cover the beginning of the fertile phase of the men-
strual cycle. To be used as a device for avoiding pregnancy, not only 
does it need to be "used in reverse" (i.e., avoiding intercourse on the 
high and peak days) but it also needs to be used along with another 
marker for the beginning and sometimes end of the fertile phase. 
The purpose of this paper is to provide evidence for the useful-
ness of the CPFM as an aid for avoiding pregnancy when used with 
another marker of fertility. In order to accomplish this evidence will 
be provided for: ( 1) the accuracy of the CPFM, (2) the effectiveness 
of the CPFM when used along with cervical mucus monitoring as 
a means to avoid pregnancy, and (3) evidence for satisfaction with 
and ease of use of the CPFM. The satisfaction and ease-of-use results 
include both quantitative and qualitative data. The conclusion will 
illustrate how the monitor can be used effectively for special repro-
ductive circumstances, such as the anovulatory state of breastfeeding, 
long menstrual cycles, and peri-menopause. 
EVIDENCE FOR ACCURACY OF THE CPFM 
Accuracy data for the CPFM comes from the manufacturer and two 
independent studies, one by researchers in Germany and the other 
by researchers in Japan. The CPFM is designed to detect the rising 
level of E3G and the surge in urinary LH. The CPFM is based on 
urinary hormonal immunoassay techniques. Detection of urinary 
metabolites of urinary estradiol (E3G) has been recognized by the 
World Health Organization (WHO) as a reliable marker for the be-
ginning of the fertile phase of the menstrual cycle (Spieler and Col-
lins 2001). Product testing has shown the ClearBlue monitor to be 
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98.8% accurate in detecting the LH surge. The CPFM detected the 
LH surge in 169 of 171 cycles from 88 women, in agreement with a 
quantitative radio immunoassay for LH (Unipath Diagnostics 2001). 
In a study with 90 women who each used the CPF M for 1-4 cycles, 
in 352 cycles with an LH surge, the first day of high fertility (i.e., the 
day of the first rise in E3G) was 3.01 ± 2.33 days before the LH surge 
(May 2001; Unipath Diagnostics 2001). 
German researchers conducted an independent study to determine 
the accuracy of the CPFM (Behre et al. 2000). They monitored 53 
female volunteers to detect daily serum levels of LH and estradiol 
and employed transvaginal ultrasound to ascertain the precise day 
of ovulation. The 53 women contributed 150 cycles of data with use 
of the CPFM, of which one cycle was determined to be anovulatory. 
Of the remaining 149 cycles, there were 135 cycles (90.6%) in which 
the CPFM detected an LH surge and there was an ultrasound-con-
firmed ovulation. In those 135 cycles, ovulation occurred 97.0% of 
the time during a three-day period that included the two "peak" days 
plus the next day "high" on the CPFM. There were no ultrasound-
detected ovulations before the monitor "peak" days. The researchers 
also found that, in 92% of the cycles, the first "high" reading on the 
monitor coincided with the serum estradiol rise day. 
Another study with 30 healthy female volunteers showed that a 
Japanese-made version of the CPFM, called the Clearview Primera 
Fertility Monitor (made by Mitsui Pharmaceuticals, Inc., in Tokyo, 
Japan), indicated up to five days of "high" fertility readings in 58.6% 
of the cycles (i.e., 17 out of 29 cycles) before the CPFM "peak" read-
ing and in 82.8% of the cycles (i.e., 24 of 29 cycles) before a labora-
tory determined urinary LH peak (Tanabe et al. 2001). The authors 
of that study concluded that the device will allow couples to use the 
information to time intercourse for the best prospects of achieving 
pregnancy. 
EFFICACY OF THE CPFM AS AN AID TO NFP 
No published studies have reported on the efficacy of the CPFM as 
an aid to avoid pregnancy. However, researchers from Germany, Ire-
land, and the United Kingdom collaborated on a study to determine 
the effectiveness of a prototype of the Persona monitor (Bonnar et al. 
1999). This study is relevant because the early prototype of the Per-
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sona had the same threshold levels for detecting E3G and LH as the 
current CPFM. The Persona study involved 710 female volunteers 
(median age 30 years, with regular menstrual cycles) who were asked 
to use the fertility monitor (without any formal training) for the 
purpose of avoiding pregnancy for a one-year period. At completion 
of the study and 7,209 cycles of use, there were 67 method-related 
pregnancies (i.e., pregnancies that resulted from having intercourse 
on a "green light" day), 92 user-related pregnancies (intercourse on 
"red light" days), and 3 pregnancies of uncertain timing. A 13-cycle 
life table analysis yielded a method (i.e., correct use) pregnancy rate 
of 12.1 %. Theoretically, the algorithm used in the current CPFM 
alone would provide this level of efficacy if used in reverse without 
other markers for the beginning and end of the fertile window. 
MARQUETTE EFFICACY STUDY OF THE CPFM 
In 2001, researchers at Marquette University initiated an efficacy 
study of using the CPFM as an aid to NFP for the purpose of avoid-
ing pregnancy (Fehring et al. 2007). A method was developed in 
which the use of the CPFM was paired with self-observation of cer-
vical mucus. Cervical mucus (both appearance and sensation) was 
rated on a 1-8 scale, with 1 being no mucus and dry sensation, and 
8 being wet and slippery sensation. The beginning of the fertile phase 
was either the presence of mucus or a high reading on the monitor 
(whichever came first), and the end of fertility was three full days 
past the peak on the monitor. 
Our study enrolled 225 couples from four cities-Atlanta, Madi-
son, Milwaukee, and St. Louis. Of the 225 couples, 195 contributed 
data for the analysis, and 30 were lost to follow-up and did not return 
data or the monitors. Mean age of the 195 female participants was 
29.4 years (SD= 5.8, range 19-42), and mean age of the male part-
ners was 31. l years (SD = 6.2; range 18-49). The participants were 
primarily Caucasian, Catholic, and at least high-school educated, 
had a mean of 1.4 children, and had combined household incomes 
greater than $50,000. None of the participants were on hormonal 
contraception or breastfeeding for at least three months before en-
rolling in the study. All participants agreed to avoid pregnancy with 
use of the CPFM for 12 months. 
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There were a total of 22 unintended pregnancies, of which three 
occurred with correct use, and a total of 1,795 documented months 
of use. The 12-month correct-use survival rate was 0.98, meaning an 
unintended pregnancy rate of2.0 per annum (95% CI= 0.96-1.00). 
The total (typical use) survival rate at 12 months was 0.86, meaning 
an unintended pregnancy rate of 14.0 per annum (95% CI = 0.82-
0.94). After that study was completed, another 20 couples met the 
criteria for the study and were added to the data set for this paper. So 
we now had a total of 215 couples and 22 unintended pregnancies, 
of which three were achieved with correct use, and a total of 1,850 
documented months of use. The correct-use unintended pregnancy 
rate was still 2.0 per annum with a 98% effectiveness and a total use 
pregnancy rate of 13.0%, or an 87% survival rate effectiveness. (See 
Table 1.) 
Table 1: Twelve-Month Correct and Typical Unintended Pregnancy Rates with 
Use of the CPFM Plus Cervical Mucus Monitoring (N = 215 couples) 
Months of Use 
3 months 
6 months 
9 months 
12 months 
Total 
# Correct Use 
Preg Rare 
1 0.995 
0 0.995 
1 0.988 
1 0.980 
3 
# Typical Use 
Preg Rate 
8 0.962 
5 0.922 
4 0.896 
5 0.871 
22 
The 215 participants contributed a mean of8.6 months of use (SD= 
3.9; median of 11 months), and 122 (56.7%) remained in the study 
for the agreed 12 months. Of the remaining 93 participants, 30 were 
lost to follow-up, 19 left to achieve a pregnancy, 18 left for personal 
reasons, and 3 left for health reasons. Of the 19 participants who in-
tended to achieve a pregnancy, 12 did so in the first cycle of trying. 
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SATISFACTION WITH THE USE OF THE CPFM AS AN 
AID TO AVOID PREGNANCY 
In order to determine the satisfaction and usefulness of the CPFM, 
we mailed a I 0-item satisfaction survey to the 195 participating 
couples of our prospective study. The IO-item survey was a short-
ened form of a satisfaction questionnaire developed by Severy for 
evaluating the Persona fertility monitor (Severy 2001). The l 0 items 
are ranked on a scale from 1 to 7, with bipolar negative and positive 
adjectives. (See Table 2 for the content of each item.) 
The survey was mailed anonymously to the 195 couples (husband 
and wife) in the study after completion of the efficacy phase. Of the 
195 surveys mailed, 65 were returned with undeliverable addresses. 
Of the 130 couples who received the questionnaires, 77 of the female 
forms (59.2%) and 71 of the male forms (54.6%) were returned. 
As seen in Table 2, the mean scores for the women ranged from 
Table 2: Ease of Use and Satisfaction with the ClearPlan Easy Fertility Monitor* 
Item Female (N = 77) M ale (N = 70) 
Ease of including monitor in daily routine 
Ease of performing urine rest 
Understanding monitor information 
Overall opinion of CPFM 
CPFM increased ability to avoid pregnanq 
CPFM decreased anxiety about pregnancy 
Ease of using the CPFM 
How do you like the CPFM 
Compared to other methods, how improved 
Chances of avoiding pregnancy 
Mean 
5.70 
6.23 
6.55 
6.15 
5.99 
5.68 
6.11 
5.92 
6.25 
5.98 
SD 
1.48 
l.02 
0.78 
l.00 
l.46 
1.42 
1.04 
1.30 
1.6 I 
1.23 
* Rating based on 1-7 scale, with 7 being the highest rared score for each item. 
Mean 
5.87 
6.1 3 
6.21 
5.93 
6.01 
5.67 
5.86 
5.89 
6.07 
6. 10 
5.68 to 6.55 and for the men ranged 5.67 to 6.21. The highest rated 
item of the IO for both the women and the men was "understand-
SD 
1.35 
1.33 
1.13 
1.28 
1.39 
1.34 
J.21 
J.28 
J.69 
J.09 
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ing the information the monitor provided." The lowest ranked item 
for both the women and the men was "to what degree has the use of 
the CPFM has decreased your anxiety about becoming pregnant." 
Overall, ease of use, information provided, and the ability to use 
the monitor to avoid pregnancy were ranked very high by both the 
husbands and the wives. 
The survey also included a section for open-ended comments. 
There were comments from 25 of the respondents. The most fre-
quent responses were (1) the test strips were too expensive, (2) the 
monitor did not always provide a warning of peak, and (3) the moni-
tor was useful in objectively defining the peak day. Following is an 
example response saying that the test strips were too expensive: 
After the birth of our third child we used the monitor briefly to avoid 
pregnancy, however, it was difficult to obtain the test sticks at various 
Walgreen's in our area. Additionally, the cost of the sticks was a fact to 
continue with the monitor. 
Following is an example from another couple: 
The sticks are too expensive and we have found another method using 
saliva that we like better. 
Following is an example response saying that there was no warning 
of the peak of fertility: 
The monitor generally did not register before my peak ovulation day. I 
had to rely completely on mucous observations pre peak. It was helpful 
identifying my peak day. 
Following is an example from another couple: 
Two days ago the monitor read a peak with no sign by mucus or moni-
tor of rising fertility. 
Following is an example response saying that the monitor helped to 
clarify the peak: 
Even if I saw mucus post peak I knew for sure I had ovulated thus 
reducing confasion. 
Following is an example from another couple: 
It only helps make rhythm a little clearer because it marks a certain 
ovulation. 
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DISCUSSION OF EFFICACY AND SATISFACTION 
Researchers have recommended using urinary hormonal markers 
(i.e., urinary metabolites of estrogen, progesterone, and LH) as indi-
cators of the fertile phase for helping women/couples to avoid preg-
nancy (Martinez et al. 1995; Martinez 1997; Crosignani and Rubin 
2000). However, there have been no published studies on how ef-
fective urinary LH indicators or the use of the CPFM could be to 
help women/couples avoid pregnancy. The current study is the first 
efficacy study of using the CPFM as an adjunct to self-observation of 
cervical mucus as a means to avoid pregnancy. 
The low correct-use unintended pregnancy rate of 2% found is 
similar to efficacy rates found with other NFP methods. Like other 
NFP methods, the CPFM plus cervical mucus self-observation over-
estimates the fertile phase. Most of the overestimation in this study 
was due to estimating fertility by use of self-observation of cervical 
mucus (Fehring, Raviele, and Schneider 2004). The mean number 
of days of fertility, as estimated by self-evaluation of cervical mucus 
based on the 1,300 NFP charts collected for this study, was 11.1 (SD 
= 3.7), and the total days of fertility estimated by the CPFM was 6.1 
(SD= 3.2). 
Although the Marquette researchers hoped to have a lower unin-
tended pregnancy rate, the 12- 14% per annum unintended preg-
nancy rate found in this study was not unexpected. This rate is lower 
than the overall typical unintended pregnancy rate of 20-25% for 
NFP methods as reported in the literature (Trussell 2004). The lower 
typical pregnancy rate could be because of the homogenous charac-
teristics of the sample, the higher education and social class of the 
sample used in this study, or the accuracy and ease of use of the fertil-
ity monitor. 
In an earlier effectiveness study of a mucus-only method at Mar-
quette University, researchers found a correct-use 12-month unin-
tended pregnancy rate of 2.0 and a use-effectiveness rate of 15.2 
among 242 couples (Fehring, Lawrence, and Philpot 1994). In com-
parison, the current study had a use-effectiveness pregnancy rate of 
11.2%. The participants for both of these studies were demographi-
cally similar. The correct-use rates are similar, but the use rates from 
the monitor plus mucus seem to be slightly better. So a question 
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could be asked whether the monitor actually adds to the efficacy of 
using mucus-only NFP methods. This question could be answered 
only by a randomized comparison study. 
Comparison of the results of this study could also be made with 
two other recent efficacy studies of NFP methods-a calendar-based 
method called the Standard Days Method (SOM) and a simplified 
version of cervical mucus monitoring called the TwoDay Method 
(TOM) (Arevalo, Jennings, and Sinai 2002; Arevalo et al. 2004). 
The correct use per annum pregnancy rates for the SOM and TOM 
were 5.60 and 4.50, respectively, and the typical or total pregnancy 
rates were 12.0 and 14.0, respectively. Although the correct-use un-
intended pregnancy rate of 2.0% for the current study is lower than 
these two studies, the differences could well be due to the poorer 
and less educated participants in the SOM and TOM studies and/or 
to the accuracy of the fertility monitor. The typical-use unintended 
pregnancy rates of the current study are similar to the SOM and 
TOM rates. However, the accuracy of the CPFM used in the current 
study might be lost when it is paired with cervical mucus observa-
tions. Furthermore, having two markers of fertility made the use of 
the CPFM plus mucus method much more complex than the sim-
pler instructions for use of the SOM and TOM. Finally, the preg-
nancy rates for the SOM and TOM rates were determined on cycles 
of use rather than months of use. 
RELATED SATISFACTION AND EASE-OF-USE STUDIES 
In a similar study on the acceptability of the CPFM, Severy (2001) 
assessed the acceptability of the Persona monitor with 220 U.S. 
women who recorded their acceptability and ease of use of the fertil-
ity device on a 7-point scale, with 1 being the least acceptable (and 
most difficult to use) and 7 the most acceptable (and the easiest to 
use). The 220 women were between the ages of 18 and 35, were in 
monogamous relationships, were sexually active, were not intending 
to have a child in the next year, and used the device for at least six 
months. The mean rating of "ease of use," like in the current study, 
was around 6, and the mean acceptability score was close to 6. The 
investigator concluded that the Persona fertility monitor was highly 
acceptable to volunteer couples and that the monitor had a positive 
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effect on the women's reproductive functioning, the women's health, 
and the couples' relationships. 
In a related study, researchers from Family Health International 
and the University of Florida conducted a study to determine the 
psychological impact of using the CPFM with 52 couples from Flor-
ida and North Carolina who used the monitor for four consecutive 
cycles to achieve pregnancy ( Severy et al. 2006). The couples also 
were provided with a multiple-item, paper-and-pencil tool to mea-
sure dimensions of acceptability for their family planning method. 
Acceptability of the monitor and having fertility-focused intercourse 
were more favorable at baseline among the couples who eventually 
achieved a pregnancy. For couples who did not achieve pregnancy, 
acceptability declined over time, and relationships became more 
strained. 
The researchers concluded that their research findings suggested 
that fertility monitoring does not have a negative influence and may 
even have a positive influence on the couples' relationship, in p ar-
ticular in enhancing communication. Although gaining knowledge 
of fertility initially helped to keep stress and anxiety at a minimum, 
stress and anxiety entered the relationship for couples that did not 
achieve a pregnancy. 
Finally, Severy and Robinson (2004) also found high acceptability 
and reproductive knowledge among 60 couple users of the CPFM 
across time (i.e., 13 cycles of use). The acceptability was higher 
among couples who became pregnant within the first three months 
of use. There have been no studies to determine the acceptability and 
ease of use of the CBFM as a device to monitor fertility and avoid 
pregnancy along with a double-check of the fertile window (i.e. , a 
fertility algorithm). 
LIMITATIONS IN USING THE CPFM 
PLUS MUCUS OBSERVATION 
The obvious limitation of the efficacy portion of this study was that 
the sample was not compared with a random selection of partici-
pants using another method of family planning. Therefore, the re-
sults could be influenced by many factors , including biases of the 
researchers and clinicians contributing to the study (Grimes et al. 
2005; Trussell 2004). 
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Another limitation is that use of two markers of fertility adds to 
the complexity of teaching and using this method of NFP. Further-
more, at times the two markers of fertility confused the participants 
(e.g., when there was a low reading on the monitor and cervical mu-
cus present, when the peak in the monitor and the peak in mucus did 
not coincide, or when there was no peak reading for the monitor). 
The confusion with the two markers was also reflected in the satisfac-
tion results when several couples mentioned they did not experience 
any high days before the peak reading of the monitor. Some couples 
would incorrectly ignore the mucus reading when they had a low 
reading on the monitor. 
Although the couple participants agreed to avoid pregnancy for 12 
months with the use of the monitor and mucus observations, some 
of the young couples discontinued the study prematurely to achieve 
a pregnancy or started to test the ends of the estimated fertile win-
dow without declaring that they were trying to achieve a pregnancy. 
We have observed that the decision to achieve a pregnancy does not 
always begin with a 100% effort. Unintended intercourse patterns 
reveal that there is often a first testing of the ends of the estimated 
fertile phase. Furthermore, although the frequency of intercourse, 
among the participants, was similar to previous studies, there was an 
underreporting of intercourse during the fertile time. This was appar-
ent when a number of participants would reveal this several months 
after the pregnancy interview. The average frequency of intercourse 
per cycle for this study was 3.85 (SD= 3.32; range 1-24), but many 
of the cycles (16%) had missing data or no recorded intercourse due 
to uneasiness of sharing that information. 
RECOMMENDATIONS 
A conservative recommendation from this study would be that 
when using both cervical mucus monitoring plus the CBFM, cou-
ples should be consistent in monitoring both markers and avoiding 
intercourse when either marker indicates a fertile day. Waiting for 
three full days after the peak in the monitor or mucus (i.e., resum-
ing intercourse on the evening of the fourth day past either peak) is 
recommended. The intercourse patterns in this study showed that 
unintended pregnancies tended to occur at the end and just out-
side of the end of the estimated fertile phase. In fact, with 13 of the 
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unintended pregnancies, intercourse occurred on either the third or 
fourth day past the last peak reading on the monitor. 
Another recommendation is to simplify the method and to use 
only the monitor as an indicator of fertility along with a simple al-
gorithm (Fehring 2005). The algorithm is based on using the earliest 
peak on the monitor from the last six cycles of charting minus six 
days as a double-check for the beginning of the fertile phase. Euro-
pean researchers have demonstrated good efficacy results with a dou-
ble-check method of NFP using the basal body temperature shift , 
cervical mucus, and a calendar-based formula (Frank-Hermann et 
al. 2005). Hopefully, simplifying the use of the monitor as a means 
to avoid pregnancy would make it easier for the couple and help to 
lower unintended pregnancies. 
A final recommendation is to conduct a randomized control trial 
of the CPFM comparing the recommended fertility algorithm with 
the use of cervical mucus alone as a method of avoiding pregnancy. 
The monitor could also be compared with the use of basal body tem-
perature (BBT) as a marker of fertility or other developed methods 
of NFP. 
USE OF THE CPFM WITH SPECIAL CIRCUMSTANCES 
In order to be useful as a method of NFP, the CPFM needs to be 
able to adapt to, and provide estimates for, fertility during special re-
productive circumstances. These special circumstances include long 
cycles, breastfeeding, and the peri-menopausal years. The CPFM is 
designed to be able to track menstrual cycles that vary from 21 to 42 
days in length. This variability in length should capture most men-
strual cycles, since at least 95% fall within 21-35 days in length 
(Fehring et al. 2006). However, menstrual cycles longer than that 
pose a problem. When menstrual cycles are longer than that on a 
consistent basis, we have the women retrigger the monitor and fast 
forward to day 5. The monitor will then test for elevated levels of 
E3G and LH for the next 20 days. 
Marquette University researchers have designed a protocol for 
women who are breastfeeding and not ovulating. The protocol en-
tails creating artificial 26-day cycles. To do this, a woman fast for-
wards the monitor to day 5 every 20 days. The monitor starts asking 
for a test on day 6 and continues testing for E3G and LH for the 
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next 20 days. The woman creates these artificial 26-day cycles until a 
peak reading is recorded followed by a menses. Results of using the 
protocol were recently reported from the first 10 breastfeeding users 
(Fehring, Schneider, and Barron, 2005). The researchers found that 
only 17% of the days during the ovulatory breastfeeding duration 
leading to the first menses were considered fertile by the monitor, 
compared with the estimated 50% of the days by self-observation 
of cervical mucus (t = 3.64, p < 0.01). Furthermore, the peak (LH 
reading) gave a clear estimate of the first ovulation before the first 
menses. 
Although the Marquette researchers do not have a protocol devel-
oped for women experiencing peri-menopausal variability, they have 
been tracking the use of the monitor with women who fall into this 
category of fertility. For the most part, the monitor is able to track 
the variability in length and estimated time of fertility. When the 
variability between long and short cycles gets too great, the monitor 
might miss the fertile phase in the very short or long cycles. How-
ever, when this happens, the woman is probably not fertile. Taffe 
and Dennerstein (2002) have demonstrated that once the running 
range between the longest and shortest menstrual cycle among peri-
menopausal women is greater than 42 days, there will be fewer than 
20 menstrual cycles left. 
CONCLUSION 
Although the CPFM was designed for couples to achieve pregnancy, 
when used along with another marker of fertility, it can be a very ef-
fective means of avoiding pregnancy. Marquette University research-
ers found that it is at least as effective as, if not more effective than, 
current NFP methods. For the most part, couples using the monitor 
found that it was easy to use, provided good information about the 
menstrual cycle, and helped to objectively estimate the fertile phase. 
Further studies need to be conducted to compare use of the monitor 
to avoid pregnancy with other methods of NFP. Finally, simplifica-
tion of using the monitor as a method to avoid pregnancy could be 
accomplished by using a simple fertility algorithm to have a double-
check for the beginning and end of the fertile phase. However, the 
monitor could be designed with the current threshold level of the 
Persona monitor and thus used without another marker of fertility. 
138 Human Fertility: Where Faith & Science Meet 
Both the current Persona and the CPFM (with another marker of 
fertility) need to be further investigated for their efficacy in help-
ing couples to avoid pregnancy and achieve pregnancy. Protocols for 
use of the CPFM with special reproductive circumstances, such as 
monitoring fertility while breastfeeding and not ovulating, continue 
to be developed. 
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